Wolfe Research initiates Stevanato stock with Outperform rating

Wolfe Research initiated Stevanato Group (NYSE:STVN) at Outperform with a $21 price target, implying about 11% upside from the $18.87 share price. The target is based on 25x-27.5x 2027 EPS and an EV/EBITDA framework, suggesting a low-$20s valuation range versus a current P/E of 31.1. Recent Q1 2026 results were mixed but constructive: EPS met expectations at EUR 0.11 and revenue beat by 1.68% at EUR 273.6 million.

Analysis

The key read-through is not just that the target is higher, but that the market is being asked to underwrite a multi-year rerating before the operating leverage shows up. In packaging, premium multiples only hold when customers believe capacity, mix, and qualification cycles are durable; that makes STVN less a “beat-and-raise” story and more a trust story around future fill rates. If the current revenue cadence persists, the stock can grind higher, but the valuation math already implies the market is discounting a clean execution path through 2027.

The more interesting second-order effect is competitive discipline. A valuation framework anchored above the peer group invites adjacent players to pursue price, capacity, or M&A to close the gap, which can compress the very premium being used to justify the target. That matters because in specialty pharma/biologics packaging, new supply does not instantly translate into market share, but it can cap pricing power and push customers to multi-source earlier than planned.

The near-term catalyst window is months, not days: follow-through depends on whether management converts top-line beats into margin expansion rather than just volume. If the market starts to believe the company is still trading at a growth multiple while earnings growth remains only mid-teens, the stock can stall even on decent prints. The bear case is not operational breakdown; it is simply that the stock has already priced in the “quality compounder” premium and needs faster EPS inflection to justify more upside.

Consensus may be missing that the easiest way for this to work is via sentiment, not fundamentals. With a modest upside target relative to an already elevated multiple, the setup is vulnerable to any small miss, lower guidance, or peer de-rating. In that sense, the risk/reward looks better for selective participation than for aggressive chase at current levels.

Key Decisions for Investors

• Hold a tactical long in STVN only on pullbacks toward the low-$18s; upside to the low-$20s is plausible over 3-6 months, but add only if management confirms margin conversion, not just revenue growth.
• Buy a short-dated put spread on STVN into the next earnings print if implied vol stays elevated; the stock is more likely to re-rate on guidance than on another modest revenue beat, giving a favorable downside hedge against a miss.
• Pair trade: long a higher-quality medtech/platform compounder vs short STVN for 1-2 quarters if you want exposure to healthcare packaging but expect multiple compression; this isolates valuation risk from sector beta.
• Use STVN as a sell-the-news candidate after any post-earnings gap up above the target zone; at current multiples, the stock needs a clear 2027 EPS upgrade to justify sustained rerating.